

GLAXOSMITHKLINE – A 100 YEAR LEGACY

GlaxoSmithKline Inc. (GSK), one of the world's leading pharmaceutical companies, has a 100-year history in Canada of helping people to do more, feel better and live longer. The company has an ongoing commitment to leadership in research and development, community investment and manufacturing.

The first legacy company, Allen and Hanbury's Company Limited, opened its headquarters in Toronto in 1902. Today, GSK employs approximately 1,800 people in Canada, who work to discover, develop, manufacture and market medicines. The company's \$250 million Canadian headquarters are located in Mississauga, Ontario.

KEY THERAPEUTIC AREAS

- Allen & Hanbury's main product, malt extract, expanded to include cod liver oil, throat pastilles and milk-based food for infants.
- In 2002, GlaxoSmithKline's key therapeutic areas include respiratory diseases, diabetes, depression and HIV/AIDS. The company is also a leader in the increasingly important area of vaccines for diseases such as Hepatitis A and B. Specifically, GSK's medicines treat:
 - Allergy
 - Asthma
 - Cancer
 - Cardiovascular disorders
 - Depression
 - Diabetes
 - Epilepsy
 - Gastrointestinal disorders
 - Herpes
 - HIV/AIDS
 - Infections
 - Migraine
 - Parkinson's Disease

RESEARCH AND DEVELOPMENT

- GSK invests more than \$100 million annually in Canadian research and development (R&D).
- The company is one of the top 25 contributors to R&D in Canada.
- GSK conducts more than 200 clinical studies annually in Canada, involving some 40,000 patients and 3,000 physicians. This represents 10 per cent of the company's worldwide clinical trials program.
- GSK employs approximately 400 highly skilled staff in the research and development of new medicines – making the company one of the largest R&D organizations in the country.
- The \$10 million *GlaxoSmithKline Pathfinders Fund for Leaders in Canadian Health Science Research* will create research positions in every Canadian medical school. The Fund was designed to help fight the brain drain by providing research opportunities for top Canadian researchers and scientists.

MANUFACTURING

- GSK's \$120 million, 250,000 square foot manufacturing facility is located in Mississauga, Ontario, adjacent to the company's Canadian headquarters.
- More than 100 medicines and 20 million units are produced annually at the facility.
- GSK has secured worldwide production mandates for its facility in Mississauga to manufacture Mepron[®], to treat pneumonia common in AIDS patients, and Malarone[®], to treat malaria.

COMMUNITY INVESTMENT

- GSK invests more than \$6.5 million annually, and is one of Canada's top ten corporate charitable donors. The GlaxoSmithKline Foundation has made a significant, long-term investment in hospice palliative care, an employee-selected cause of choice, donating 50 per cent of its proceeds toward this cause.
- Since 1990, GSK has donated more than \$11 million in medicines through Health Partners International Canada to supply critical medical treatments to those who are in need due to poverty, natural disasters and other causes in such countries as Turkey, Cuba, Honduras and Nicaragua.
- Most recently, GSK invested \$2 million in asthma education and management, through the establishment of two GlaxoSmithKline Asthma Education Centres at the Trillium Health Centre and the Credit Valley Hospital in Mississauga.

AWARDS

- GSK was named one of the top 50 companies to work for in Canada by The Globe & Mail's Report on Business magazine for 2002. This ranking is based on employee opinions, employment practices and management leadership.
- The company has received several Prix Galien Awards, the highest honour in the Canadian pharmaceutical industry. For example, 3TC[®] (lamivudine), developed by GSK and discovered by Biochem Pharma, would prove to be the most important drug discovery in Canada since insulin, improving the longevity and quality of life for people living with HIV/AIDS. In 1997, the companies won a Prix Galien Award for the product.
- GSK, along with the Canadian Hospice Palliative Care Association, was awarded the Imagine Caring Company "New Spirit of Community" Partnership Award in 1999 for Living Lessons[®], an ambitious public awareness program aimed at significantly raising hospice palliative care from the periphery of the health-care system into the mainstream, promoting quality end-of-life care for all Canadians.

**For further information, please contact:
Corporate Communications
GlaxoSmithKline
Tel: 905 819-3000**

"Mepron" and "Malarone" are registered trademarks, used under license by GlaxoSmithKline Inc.

"3TC" is a registered trademark, used under license by GlaxoSmithKline Shire BioChem.

"Living Lessons" are registered trademarks, GlaxoSmithKline Inc.